摘要
目的 探讨低分子肝素抗凝（海普宁）治疗急性脑梗死（脑血栓形成）的治疗效果及其安全性.方法 急性脑梗死171例分别应用低分子肝素抗凝（海普宁）治疗96例及常规治疗组75例治疗各7天.两组7天后继续应用生脉注射液40ml＋NS 250ml,IV,gtt,Qd,14天.结果 抗凝治疗组经治疗21天后基本治愈者16.67%,显著好转率为77.72%,恶化及死亡率为2.08%,神经功能缺损评分在治疗第7天后有非常显著好转（T=7.16,P＜0.001）;常规治疗组21天后基本治愈率为12.00%,显著好转率为56.00%,恶化及死亡率分别为10.80%,神经功能缺损评分在第14天后有显著提高（T=1.96,P＜0.05）.抗凝治疗组、常规治疗组均无颅内出血.抗凝治疗组的显效率非常显著高于常规治疗组（χ2=38.19,P＜0.001）.3个月时复发率,常规治疗组显著高于抗凝治疗组（10.67%和1.04%, χ2=6.01,P＜0.05）.结论 本组资料提示,急性脑梗死的治疗应用低分子肝素抗凝治疗为优,且复发率明显低.应用低分子肝素抗凝治疗时低分子肝素的剂量和用法掌握恰当,则可避免并发颅内出血,并可取得满意疗效.
Objective A control comparison of therapeutic efficacy for the treatment of acute cerebral infartion was made betweengroup treated with antiagglutination （ low molecular weight heparinoid, LMWH） for 96 cases and that treated with normal way for 75 cases. The time of drug use in both groups all was within 48 hours after the onset of the acute cerebral infartion. Methods The methods of treatment were. LMWH 5000U each time, hypodermic injection, twice a day for 7days for the treated antiagglutination group and normal way for the treated normal way group. Results The results showed that the improvements of nervous function of the antiagglutination group was very significantly superior to the normal way group, Rate of cure effect were 16.67% and 12.00% and rate of striking effect were 77.72% and 56.00%, respectively. No one case of antiagglutination group had bleedung and normal way group no adverse reaction. Conclusions The data indicated that effect of this med- icine was apparent, safe with little side effects. LMWH are suitable for early use.
